FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer

FDA granted accelerated approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

Source: FDA Center for Drug Evaluation and Research - What's New - April 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news